Vonosap pack 400, Vonosap pack 800 and Vonopion receive approval in Japan.
+ Technology/Innovation
Jamie Barrand | Feb 27, 2016

Japanese pharmaceutical companies gain approval for new stomach bacteria therapies

Japanese companies Takeda Pharmaceutical Co. Limited and Otsuka Pharmaceutical Co. Ltd. have received New Drug Application approval from the Ministry of Health, Labor and Welfare for Vonosap pack 400, Vonosap pack 800 and Vonopion.

This approval comes as a result of Takeda's efforts to eradicate Helicobacter pylori. Each of the three therapies can be used to treat bacterial infection.

Vonosap is marketed in a blister pack that contains one tablet each of acid suppressant Takecab, Amolin -- a brand name for antibiotic amoxicillin -- and Clarith, the antibiotic clarithromycin. Vonopion is a triple-drug blister pack of one tablet each of Takecab, Amolin and Fragile, which is a brand name for metronidazole, an antibiotic and antiprotozoal medication.

Helicobacter pylori is a Gram-negative, microaerophilic bacterium. It typically infects the stomach, causing chronic gastritis and gastric ulcers.

More than half the people in the world harbor the bacterium in their upper gastrointestinal tracts, although infections happen more often in underdeveloped nations.

Organizations in this story

More News